{"filing":{"accession_number":"0001193125-26-399425","cik":"0001232524","ticker":"JAZZ","company_name":"Jazz Pharmaceuticals plc","form":"8-K","filing_date":"2026-09-23","report_date":"2026-09-23","primary_document":"d163027d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1232524/000119312526399425/d163027d8k.htm"},"events":[{"id":34598,"run_id":31839,"accession_number":"0001193125-26-399425","anchor_item_number":"1.01","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"Jazz Pharmaceuticals entered into Amendment No. 4 to its Credit Agreement on September 23, 2026, converting existing Tranche B-2 Dollar Term Loans into new Tranche B-3 Dollar Term Loans totaling $1,895,000,000 with an extended maturity date (May 5, 2033, from May 5, 2028) and repriced interest margins (reduced by 50 basis points).","company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","filing_date":"2026-09-23","form":"8-K","submitted_at":null,"items":[{"id":38361,"accession_number":"0001193125-26-399425","item_number":"1.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Jazz Pharmaceuticals entered into Amendment No. 4 to its Credit Agreement on September 23, 2026, which involved converting existing Tranche B-2 Dollar Term Loans into new Tranche B-3 Dollar Term Loans totaling $1,895,000,000 with an extended maturity date (May 5, 2033, from May 5, 2028) and repriced interest margins (reduced by 50 basis points). This constitutes a material amendment to an existing direct financial obligation—the creation of a new class of term loans with modified terms. While this is technically a refinancing/repricing rather than a wholly new debt issuance, it involves the creation of a new tranche of debt securities with modified terms and is disclosed under Item 1.01 (Material Definitive Agreement), making it a debt-related capital event material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T20:24:15.891341+00:00","company_name":"","ticker":null,"filing_date":""},{"id":38362,"accession_number":"0001193125-26-399425","item_number":"2.03","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Item 2.03 explicitly addresses \"Creation of a Direct Financial Obligation,\" which is the standard disclosure item for debt issuances, credit facilities, and new financial obligations. The incorporation by reference to Item 1.01 (a material agreement item) suggests a substantive debt transaction. While the specific details are not provided in this excerpt, the Item 2.03 heading and structure indicate a debt issuance or similar financial obligation event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T20:24:15.891341+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38361,"accession_number":"0001193125-26-399425","item_number":"1.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Jazz Pharmaceuticals entered into Amendment No. 4 to its Credit Agreement on September 23, 2026, which involved converting existing Tranche B-2 Dollar Term Loans into new Tranche B-3 Dollar Term Loans totaling $1,895,000,000 with an extended maturity date (May 5, 2033, from May 5, 2028) and repriced interest margins (reduced by 50 basis points). This constitutes a material amendment to an existing direct financial obligation—the creation of a new class of term loans with modified terms. While this is technically a refinancing/repricing rather than a wholly new debt issuance, it involves the creation of a new tranche of debt securities with modified terms and is disclosed under Item 1.01 (Material Definitive Agreement), making it a debt-related capital event material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T20:24:15.891341+00:00","company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","filing_date":"2026-09-23"},{"id":38362,"accession_number":"0001193125-26-399425","item_number":"2.03","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Item 2.03 explicitly addresses \"Creation of a Direct Financial Obligation,\" which is the standard disclosure item for debt issuances, credit facilities, and new financial obligations. The incorporation by reference to Item 1.01 (a material agreement item) suggests a substantive debt transaction. While the specific details are not provided in this excerpt, the Item 2.03 heading and structure indicate a debt issuance or similar financial obligation event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T20:24:15.891341+00:00","company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","filing_date":"2026-09-23"}]}